The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company reported group revenue of US$230 million, up 11% quarter-over-quarter, and reaffirmed its FY 2026 revenue guidance.
What did Telix Pharmaceuticals report?
- Unaudited group revenue of US$230 million, up 11% from the previous quarter
- Precision Medicine revenue of US$186 million, a 16% quarter-over-quarter increase
- FY 2026 revenue guidance reaffirmed at US$950 million to US$970 million
- Successful early results from Phase 3 ProstACT® study of TLX591-Tx for prostate cancer
- Key regulatory submissions: Pixclara® NDA resubmitted to the US FDA and Pixlumi® MAA filed in Europe
What else do investors need to know?
Telix continues to advance its therapeutics pipeline, hitting milestones in global studies across prostate, brain, and kidney cancer. Notably, the company observed no new safety signals in the first part of the ProstACT study, supporting the safety profile of its lead prostate cancer candidate.
The company maintains strong momentum in its global expansion, now offering Illuccix in 21 countries, including 16 European nations. Its commercial presence is poised to support future product launches in both diagnostics and therapeutics.
Board renewal is underway, with David Gill set to join as Non-Executive Director in May and be appointed Chair in the future, bringing recognised governance and industry experience.
What did Telix Pharmaceuticals management say?
Managing Director and Group CEO Dr. Christian Behrenbruch said:
Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two-product PSMA imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.
What’s next for Telix Pharmaceuticals?
Telix reaffirmed its FY 2026 revenue guidance, expecting further revenue growth driven by global uptake of its products and a full-year contribution from RLS Radiopharmacies. The company is targeting increased scale through new product launches and expanding its clinical program footprint across many markets.
R&D spend for the full year is forecast between US$200 million and US$240 million, subject to commercial progress. Telix is also moving forward with additional regulatory filings and study site activations in new countries, supporting a positive outlook for its pipeline.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 17% over the same period.
The post Telix Pharmaceuticals Q1 2026: Revenue growth, guidance reaffirmed appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Ramelius Resources confirms guidance, strong March quarter gold output
- Bank of Queensland announces $3.7bn loan sale and capital partnership with Challenger
- Guzman y Gomez posts 20% Q3 FY26 sales growth
- NEXTDC announces $1 billion hybrid securities offer and La Caisse backing
- 5 things to watch on the ASX 200 on Tuesday
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.